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1. Introduction 
1.1 Glioma 
Malignant gliomas are the most common types of brain tumors in adults. These tumors are 
highly invasive and despite multi- modality treatment, the mean survival time of patients is 
still less than a year (Machado et al., 2005). Gliomas, a cancer of glial cells constitute more 
than 90% of all primary malignant central nervous system (CNS) tumors. Although gliomas 
are the most common major subgroup of primary nervous systems tumors, their etiology is 
less well understood than is the etiology of the other two major subgroups: meningiomas 
and neuromas. The development of glioma is a complex process with the involvement of 
both oncogenes and tumor suppressor genes in the accumulation of genetic lesions (Zhang 
et al., 2005). Brain tumors arise as a result of gradual accumulation of several genetic 
aberrations in precursor cells which can occur either at the chromosomal level or at the gene 
expression level (Furnari et al. 1995). Despite considerable efforts to unravel the etiologic 
basis for this cancer and attempts to find a cure, gliomas largely remain refractory to 
treatment. Except for a small percentage of cases, the tumors continue to show high 
morbidity and mortality (Wrensch et al. 2005). The identification and evaluation of the 
cellular sites in which such genes and their encoded proteins are expressed, could help us to 
determine how those cellular expression sites are linked to the convoluted circuits of 
neurons that control brain function. To date, there is major technological challenge in the 
capability to detect and map genes whose expression is altered either by the disease’s 
process or by the cells adaptations to resist the disease’s process (Bloom et al., 2004). 
1.2 Primary culture 
Primary culture is the initial culture established from an individual which represents the 
environment most closely related to the original cell. The availability of unlimited number 
of cells and the possibility of performing multiple,  repetitive experiments over long period 
of time renders cultured tumor cells a valuable mean for preliminary assessments of new 
therapeutic agents (Bakir et al., 1998). Development of biotechnology methods including 
primary culture technique gives us the opportunity to study the malignant glioma in depth 
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in order to understand the etiology of the brain tumor especially on gene regulations and 
cellular pathway mechanisms.   
1.2.1 Primary culture: explant technique 
Primary explant technique is one of the primary culture techniques. It was the original 
method developed by Harrison (1907) and Carrel (1912), and others for initiating a tissue 
culture. As originally performed, a fragment of tissue was embedded in blood plasma or 
lymph, mixed with heterologous serum and embryo extract, and placed on a coverslip that 
was inverted over a concative slide. The clotted plasma held the tissue in place, and the 
explant could be examined with a conventional microscope. The heterologous serum 
induced clotting of the plasma, the embryo extract and serum, together with the plasma, 
supplied nutrients and growth factors will stimulate cell migration from the explant. This 
technique is still being used but has been largely replaced by the simplified method. First of 
all, the tissue is chopped finely and rinsed, the pieces are seeded onto the surface of a 
culture flask or petri dish in a small volume of medium with a high concentration of serum, 
such that surface tension holds the pieces in place until they adhere spontaneously to the 
surface. Once this is archieved, outgrowth of cells usually follows. 
1.3 Glioma primary culture 
The established glioma primary culture gives us permanent material to examine the 
expression of proteins of interest and their functional characterization in vivo and in vitro. 
For that reason, we developed our very own primary culture of the cancerous glioma from 
local clinical tumor sample so as to understand better its genetic background and cellular 
development.  Establishing primary glioma cell line in culture, the malignant cells will 
represent an excellent permanent representative material for molecular and cellular 
characterization of tumor supported with specific antigenic identification and biochemical 
characterization of cellular proliferation (Tomaso et al., 2000; Halfter et al., 1998; Pohl et al., 
1999; Grippo et al., 2001; Machado et al., 2005).  In this study, we used four well known 
antigens such as GFAP (Glial Fibrillary Acidic Protein), which has been shown to be a 
marker of glial cell origin (Zhang et al., 2005), S-100 protein which was originally identified 
as a brain specific marker (Machado et al., 2005), Vimentin which has been detected in a few 
primary cultured glioma (Bakir et al., 1998) and positive expression of BORIS protein in 
glioma (D’Arcy et al., 2006).   
1.4 Transcription factor in cancer development 
Cancer is known to be a pathophysiological condition with many different genes involved 
including transcription factor as a main. Transcription factor is a molecule that participates, 
alone or as part of a complex, in the binding to a gene’s enhancer response element or 
promoter. Transcription factors also known as regulatory proteins which have an ability to 
bind to specific DNA sequences (Nebert, 2002). Transcription factor have two separate 
protein domains called a DNA binding domain and a regulatory domain. DNA binding 
domain binds to their specific DNA binding sites and the regulatory domain modulates 
transcription. The DNA binding domain interacts with the promoters and the regulatory 
domain allows interaction with other transcription factors. The binding of the transcription 
factors activates (or  in some cases, to inhibits) transcription of the specific DNA  with the 
ultimate outcome being the up- or down-regulation of expression of that gene (Nebert, 2002, 
Theresa Phillips, 2008) which leads to the production of the gene’s end product; mainly in 
protein form or in certain circumstances without production of functional end product.  
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1.4.1 BORIS as a transcription factor and cancer testis antigen (CTA) family 
BORIS is one of the transcription factors which believed to play role in cancer development. 
Human BORIS (Brother of the Regulator of Imprinted Sites) gene maps to chromosome 
20q13.2 (Loukinov et al, 2002). This chromosome region is often amplified in many cancers 
and is believed to contain a dominant immortalising or transforming gene(s).  
 
 
 
Fig. 1. BORIS map to cancer-associated ‘hot spots’ on HUMAN CHROMOSOME 20q13. 
(Modified from Klenova et al., 2002) 
BORIS is a conserved, ubiquitous, and highly versatile 11-zinc-finger transcription factor 
involved in various aspects of gene regulation, forms methylation-sensitive insulators that 
regulate X chromosome inactivation and expression of imprinted genes. It is a multivalent 
Zinc Finger transcription factor which present only in the testis and expressed in a mutually 
exclusive manner with CTCF (CCCTC- binding factor) Zinc Finger transcription factor 
during spermatogenesis. BORIS is paralogous to CTCF and thus has the same DNA-binding 
potential, but with distinct amino and carboxy termini (Loukinov et al., 2002). Under normal 
physiologic conditions, BORIS is predominantly expressed during embryonic male germ 
cell development. However, BORIS is also expressed in tumors and cancer cell lines 
including glioma and it has been classified as a cancer-germ line or cancer-testis gene 
(Nguyen et al., 2008). Since BORIS bears the same DNA-binding domain that CTCF employs 
for recognition of methylation marks in the soma, it was identified as a candidate protein for 
the elusive epigenetic reprogramming factor acting in the male germ line (Loukinov et al., 
2002). Other than glioma, recent studies reported that BORIS is aberrantly expressed in 
various cancer cell lines including uterine cancer and breast cancer (Klenova et al. 2002; 
Loukinov et al. 2002;Hoffmann et al., 2006; Risinger et al.; 2007, D'Arcy et al., 2008).  
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Fig. 2. Exon- Intron structure of BORIS is shown. The 11 Zn fingers are positioned in exons 
E3 through E8, with several individual fingers being separated between neighbouring 
exons.  Exon 10 harbours the stop codon and a long 3'- UTR. (Klenova et al., 2002) 
BORIS has been implicated in the initiation of a series of methylation events at the 
imprinting control regions, in the vicinity of the CTCF-/BORIS-binding sites which may be 
significant for cancer development (Jelinic and Shaw, 2007). However, recent study by 
Renaud et al. (2007) reveal that the regulation of BORIS activity is complex and being both 
promoter- and cell type-dependent. Varying promoter usage driving multiple BORIS 
transcripts influence many aspects of epigenetic reprogramming in normal development 
and also in tumorigenesis. 
BORIS belongs to the cancer testis antigen (CTA) family which its genes products exhibit 
highly tissue-restricted expression and are immunogenic in cancer patients (Vatolin et al., 
2005, Risinger et al., 2007). The function of the majority CTAs is still unknown; however, 
some CTAs may play role in a regulation of gene expression and others in gametogenesis 
(Old, 2001; Kalejs & Erenpreisa, 2005). The CTAs are attractive targets for developing 
cancer-specific therapy due to their highly restricted expression in normal tissues and broad 
expression in a wide range of tumors (Risinger et al., 2007). Studies by Hong et al., (2005) 
and Vatolin et al. (2005)  reveal that the expression of BORIS correlated with and induced 
the expression of other cancer testis genes MAGE-A1 and NY-ESO-1.  
The main focus of this study was to reveal the expression of BORIS protein as well as 
morphological characteristics of this newly established clinical derived glioma primary cell 
line. BORIS has been selected in this study due to its physical and functional related to 
CTCF, multifunctional transcription factor. BORIS which also known as CTCFL (CTCF-like), 
is the mammalian paralog of a highly conserved (Pugacheva et al., 2006), multi-functional 
chromatin factor encoded by a candidate tumor suppressor gene, CTCF; CCCTC- binding 
factor (Ohlsson et al., 2001).  Loukinov et al., (2002) showed that, both BORIS and CTCF 
encode polypeptides of similar size that share a centrally positioned nearly identical DNA-
binding domain (DBD). The DBD is composed of 11 Zn-fingers (11ZF), including ten of the 
classic DNA-binding C2H2-class and one (ZF 11) of the C2HC-class capable of binding both  
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Fig. 3. Comparison of protein motifs in BORIS and CTCF. The best-fit alignment of the 
human CTCF and BORIS polypeptides produced by the GCG-package of programs with 
zero-penalty for the gap extension. Identical and similar amino acids are shown by red 
letters. The CxxC and HxxxH invariant residues involved in Zn-coordinated formation of 
the C2H2-ZF structures are shown by outlined letters in a bigger font. The near-identical 
ZFs, numbered 1–11, are highlighted by a gray background, and the critical base-
recognizing residues at positions−1, 2, 3, and 6 inside of each ZF are shown by blue letters. 
Dashed lines show the gaps introduced to reveal minor similarities outside of the ZF-
domains. The major Ser-phosphorylation sites and the putative additional DNA-binding 
‘AT-hook’ motif, conserved in vertebrate CTCF proteins but absent in BORIS proteins, are 
shown by outlined letters. The most likely sites for K/R-acetylation and K-methylation, 
similar to those in the H3 and H4 histones, are highlighted in green. The experimentally 
determined acetylation site in the K/R-rich CTCF region downstream of the 11th ZF, and a 
homologous site in BORIS, are underlined in addition to green background that shows 
major H3-like putative K-methylation sites in both proteins. (Klenova et al., 2002) 
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single-strand DNA and RNA (Ladomery & Dellaire, 2002). It is remarkable that the 11 ZF 
DBD regions in BORIS and CTCF are encoded by genomic sequences, which present an 
accurate duplication of a region containing all ZF-coding exons of the CTCF gene from an 
early mammal. The accuracy of this duplication in the human genome was maintained to 
the extent that genomic nucleotide similarities between CTCF and BORIS at individual 
intron–exon junctions approach 100% identity at the single nucleotide level (Loukinov et al. 
2002). Due to this shared DNA-recognition domain, BORIS can bind specifically to the same 
DNA target sequences that interact with CTCF. However, the consequences of BORIS or 
CTCF bound to the same site would be different because the amino- and carboxy-termini of 
BORIS and CTCF are totally unrelated (Klenova et al, 2002; Loukinov et al, 2002;  Campbell 
et al., 2010). And the different functional outcomes depending on which one of the two 
paralogs occupies a CTCF/BORIS-11ZF binding site (Vatolin et al., 2005). 
2. Materials and methods 
2.1 Patient and tumor 
Malignant glioma was obtained directly from the operation theater , Hospital Universiti 
Sains Malaysia Kubang Kerian, Malaysia with the permission from the Human Ethical 
Committee, Universiti Sains Malaysia (Reference number: USM/ PPSP/Ethics Com/ 2006 
(179.5(2). The sample was derived from an adult male patient with recurrent glioblastoma 
multiforme. After surgery, the sample was immediately transferred into sterile falcon tube 
and transported in ice to the laboratory for subsequent culture. The cell line has been 
successfully cryopreserved and passaged up to 32 times.  
2.2 Primary culture work 
2.2.1 Preparation of sterile complete media RPMI 1640 (50mL) 
10mL pre- warmed Fetal Bovine Serum (Sigma, USA) was poured into a sterile falcon tube 
(50mL). 1mL of penicillin-streptomycin and 100µL antibiotic cocktail (kanamycin, 
gentamycin, streptomycin, ampicillin, penicillin and chloramphenicol with total working 
concentration 50µg/ mL) (Sigma, USA) were added into the same falcon tube. Finally, RPMI 
1640 with L-Glutamine and NaHCO3 (HyClone, A Perbio Science Company) was added 
until the mixture volume became 50mL. Then, the completed media was dispensed into 
another sterile 50mL falcon tubes after filtering it through 0.22 micron (μm) membrane filter. 
The media was kept in 40C refrigerator until use. 
2.2.2 Glioma culture 
As for the primary culture technique, we chose the explant method developed by Harrison 
(1907) and Carrel (1912) for initiating the culture of clinically derived glioma tissue since it 
was a type of soft tissue and in most cases, we only managed to take out a very small 
amount. Based on local adaptation to our operation theatre (OT), we added a few extra steps 
to modify the standard explant method to reduce or to eliminate possible contamination at 
the early stage. For that purpose, the addition of antibiotic cocktail in the complete culture 
media and the pre-rinsing of the collected tissue with 70% ethanol before culturing in the 
flasks help us in achieving that goal. In addition, full cooperation from the neurosurgeons 
and OT staffs in avoiding cross contamination between surgical procedure, careful retrieval 
of the clinical sample from the patient’s brain and careful transportation of collected sample 
from the OT to our culture laboratory also helped to reduce and eliminate contamination. 
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The tumor was given a quick rinse in 70% ethanol to disinfect all the possible 
microorganisms, followed by a brief rinse in sterile 1x PBS (Sigma, USA) to wash out the 
ethanol and also the blood. The tumor was then placed in a sterile petri dish filled with 
complete culture media and minced into fragments sized 1-2 mm by using a sterile blade in 
sterile complete medium RPMI 1640 with L-Glutamine and NaHCO3 (refer to 2.2.1). The 
fragments were then layered on the bottom of plastic flasks (25 cm2) and 3mL of the 
complete medium was poured gently into the flask to avoid detachment of the tissue 
fragments. The culture was incubated at 37oC in a humidified atmosphere of 5% CO2 for 
about 5-7 days (Figure 1). Once the cells had migrated out and attached to the bottom of the 
flasks, medium was changed after intervals of 48- 72 hrs. 
 
 
 
 
Fig. 4. Primary cell culture; steps in processing the clinical samples. (A) Materials used to 
culture clinical tissues   (        ); i- 70% ethanol to disinfect the tissues; ii- sterile PBS to rinse 
the tissues; iii- complete media RPMI 1640 wherein tissues been minced  to small pieces. (B) 
Minced tissues transferred into cell culture flask with complete media RPMI 1640. (C) 
Volume of the complete media RPMI 1640 sufficient for the minced tissue contact to the 
bottom of the inner flask surface. (D) Labeled flask is ready to be placed in humid CO2 
incubator 
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When the primary culture reached confluence the cells were sub-cultured by treatment with 
0.05% trypsin and 0.02% EDTA and maintained in the same medium. Subsequently the 
cultures were serially sub-cultured using the same procedure. Large quantities of this 
glioma cells were routinely frozen at various passage levels in 95% fetal bovine serum plus 
5% DMSO (v/v) for future use. 
2.3 Image analysis work: phase contrast microscopy  
The cellular glioma cultured cells at various passages were grown in sterile cell culture 
flasks. The cultured cells were observed and photographed using an inverted microscope 
fitted with a camera (Axiovert 25 ZEISS with 0.5 X magnifier software evolution LC Kit and 
Image Pro- Express software). 
2.4 Confirmation of cell line establishment based on marker antigen 
2.4.1 ProteinExpression: SDS-PAGE & western blotting 
The human malignant glioma cells were cultured in 75cm2 flasks. Subconfluent tumor cells 
were collected after incubation with 0.25% trypsin and 0.02% EDTA, and washed once with 
pre- cooled PBS. The neutralization of the trypsin was done by the addition of pre-cooled 
complete medium. The detached cells suspension was spun down by centrifugation at 
1500rpm for 5 minutes. The supernatant was discarded and the pellet was washed with pre-
cooled sterile 1x PBS. Following centrifugation, the supernatant was discarded and the 
pellet was lyzed with pre- cooled radioimmunoprecipitation assay (RIPA) buffer (0.4 M 
NaCl, 50 mM Tris pH 7.5 (by HEPES), 1% NP- 40, 0.1% SDS, 0.1% Na deoxycholate, 1mM 
EDTA, 1mM PMSF ) overnight at 4oC . The next day, the suspension was spun at 10, 000 
rpm for 20 minutes at 4oC and the supernatant was then extracted. Protein samples with 
concentration of approximately 0.72 mg/mL were mixed with an equal volume of 2x 
loading dye/ treatment buffer and then heated at 950C for 5 minutes. Samples were 
electrophoresed in gradient (12.5% and 10%) SDS-PAGE. Once electrophoresis was 
completed, the proteins were visualized either by staining with commasie blue or by 
western blotting. SDS- PAGE used in this study was a modified of Laemmli system 
(Laemmli, 1970).  
After electrophoresis, gels were electroblotted onto the PVDF membrane (MILLIPORE 
Immobilon P- Transfer membrane). The membrane was treated with 5% skim milk for 1 
hour. After washing with the washing buffer, the membrane was then incubated with 
primary antibody; GFAP (abcam), Vimentin (abcam) or BORIS (Santa Cruz) for 1 hour at 
room temperature. Following three times (5 minutes each) washes in washing buffer, the 
membrane was treated with anti- mouse or anti- rabbit immunoglobulin antibody 
conjugated with Horse-Radish Peroxidase (HRP) for 1 hour at room temperature. A final 
wash was performed, and the membrane was equilibrated with detection buffer ECL 
solution (Immobilon Western Chemiluminescent HRP Substrate) for about 3 minutes and 
the membrane was placed in developing folder on the hypercassette (Amersham Life 
Science). In the dark room, the film (Kodak X- Omat LS Film Sigma- Aldrich) was exposed 
to the membrane for about 10 minutes before it was developed accordingly. 
2.4.2 Immunocytochemistry 
Immunocytochemical analysis of neuron- glial markers ( Beta III- Tubulin, MAP2, 
Oligodendrocytes and GFAP) were performed using specific antibodies purchased ; neuron- 
glial cell marker sampler kit from Millipore, Chemicon whereas the other glial markers (S-
www.intechopen.com
 The Expression of BORIS Protein in a Newly Established Primary Glioma Cell Culture Line 
 
447 
100 and vimentin) and BORIS were performed using specific antibodies purchased from 
Abcam and Santa Cruz respectively. IHC Select HRP/ DAB (Millipore, Chemicon) kit was 
used as the secondary antibody system in this analysis.  
Briefly, cultured glioma cells were harvested at a specific passage, trypsinized and cultured 
in new chambered slides. When the cells in each chamber reached semi confluent, the 
medium was discarded, washed with sterile 1X PBS plus 0.05% tween 20. The slides were 
then fixed in cold methanol for 20 minutes at 4o C. After a thorough wash with  0.05% tween 
20 in 1X PBS, the cells were treated with all of the above primary antibodies according to the 
manufacture's instructions. The bound primary antibody was detected using peroxidase 
labeled polymer conjugated to either mouse or rabbit secondary antibodies. Subsequently, 
the slides were incubated with a substrate mixture of 3, 3- diaminobenzidine (DAB) and 
0.02% H2O2. Cells were then counterstained with haematoxylin. Negative control slide was 
also included by omission of the primary antibody. 
2.5 Growth curve 
Glioma cells were collected from the 16th passage for determination of growth curves. 
Briefly, semi confluent cultures were trypsinized and cells resuspended in complete 
medium for counting. Cells (1 × 104) were plated into each well of a 12-well plate and counts 
from triplicate wells were made daily for 8 days. Trypsinized cells were counted in 
haemocytometer chamber and numbers were averaged for each time interval. Cell 
population doubling time was calculated from the linear phase of the growth curve, and the 
saturation density was the plateau point on the growth curve after the linear growth phase. 
2.6 Real-time PCR analysis 
Total RNA from cell lines (~1x107 cells) were extracted using RNeasy Mini Kit (Qiagen, 
Germany) and checked for concentration, integrity and purity.  Two microgram of total 
RNA was reverse transcribed into cDNA using Revert Aid H Minus First Strand cDNA 
Synthesis Kit (Fermentas, USA). The BORIS primers and probe were the same as previously 
published by D’Arcy et al., (2006); the sequences (64bp) were as follows, forward: 5’-
CCCATTGTGCCACCATCA-3’, reverse: AGCATGCAAGTTGCGCATAT--3’, and probe: 
6FAM-ACGGAAAAGCGACCTAC-MGB; they were purchased from Applied Biosystems, 
USA.  Real-time PCR analysis with optimal condition was performed using Taqman probe 
Master Mix (ABI, USA) via Applied Biosystems 7500 Real-Time PCR System (USA). The 
Real-time PCR products were also subsequently subjected to 2% agarose gel electrophoresis 
for the confirmation of PCR amplicons. 
3. Results and discussion 
Working in a high humidity and tropical condition exposed our clinical sample to bacterial 
and fungal contamination. Indeed, it is one of the constraints in the establishments of any 
primary tumor culture taken from a clinical source. We established an antibiotic cocktail that 
we used in our initial complete media which consists of amphotericin B (fungizone), 
gentamycin, chloramphenicol, kanamycin and ampicilin. The concentration of the cocktail 
used in this study varies depending on the severity of contamination in the initial condition 
of our clinical samples. A referral to a comprehensive pharmacology guide for antibiotic-
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cellular incompatibilities information was very important when we were using two or more 
antibiotics in the same culture system because combined antibiotics frequently exert 
cytotoxic effects at lower concentrations than those indicated as appropriate for the 
individual antibiotics (Sigma-Aldrich.inc). In this case, we have started the cocktail addition 
at the lowest concentration possible. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Morphology of the clinical derived glioblastoma multiforme primary cell line at the 
initial stage; Attached tissue fragment (          ). (A) 10 X magnification; (B) 20 X 
magnification; and (C) 40 X magnification. 
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Fig. 6. Morphology of the clinical derived glioblastoma multiforme primary cell line at passage 1; 
rounded cells and dendritic-like cells with extensive cytoplasmatic prolongations (        ).  
(A) 10 X magnification; (B) 20 X magnification; and (C) 40 X magnification. 
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Fig. 7. Confluent monolayer of the clinical derived glioblastoma multiforme primary cell 
line with rounded and dendritic-like cells. (A) 10 X magnification; (B) 20 X magnification; 
and (C) 40 X magnification. 
Variable morphological features could be found in the glioblastoma multiforme cells i.e 
small rounded cells and dendritic- like cells with extensive cytoplasmatic prolongations 
(figure 2, figure 3 and figure 4). Our finding was in agreement with other works in literature 
that showed evidences suggesting that some types of cancers, notably solid tumors,were not 
homogeneous in their cell composition but are composed of heterogeneous cell types 
(Bigner et al.,1979, 1981; Perzelova et al., 1998; Grippo et al., 2001; Machado et al., 2005). 
Similar morphological features were observed throughout serial passages, as described. This 
tumor cell line presented features of malignant glioma characterized by cell pleomorphism, 
necrosis and aggressive growth (Machado et al. 2005; Grippo MC et al. 2001). Low passage 
cultures grew slower than high passage cultures. This fact could indicated a perfect 
adaptation of cells to the culture conditions. This cell line would be useful for testing 
potential anticancer agents either in vitro or in vivo.  
www.intechopen.com
 The Expression of BORIS Protein in a Newly Established Primary Glioma Cell Culture Line 
 
451 
 
 
Fig. 8. Western Blotting of the clinical derived glioblastoma multiforme (rGBM) primary cell 
line. 
Western blotting of total lysate of DBTRG-05MG (ATCC derived glioma) and primary 
culture cell glioblastoma multiforme (rGBM) separated in SDS-PAGE and probed with: 
(A) α-BORIS  polyclonal  (dilution 1:500). The presence of BORIS  is indicated by red 
arrow at ~76 kDa for both  DBTRG-05MG and rGBM. 
(B)  α-GFAP monoclonal  (dilution 1:500). The presence of GFAP is indicated by red 
arrow at ~50 kDa to  ~57kDa for  both  DBTRG-05MG and rGBM. 
(C)  α-Vimentin monoclonal  (dilution 1:500). The presence of vimentin  is indicated 
by red arrow at ~50 to ~57 kDa for both DBTRG-05MG and rGBM. 
Western blot analyses showed strong expression for BORIS protein (figure 8, A). BORIS is a 
CTCF paralog, which contains all eleven zinc fingers of CTCF, and has been shown to 
promote cell growth leading to transformation (Loukinov et al., 2002). One mechanism of 
action by which BORIS is thought to cause cancer through interference is the maintenance of 
an appropriate methylation pattern in the genome (Klenova et al., 2002). The detection of 
BORIS protein in glioblastoma multiforme suggested its potential as an early marker of this 
type of glioma since BORIS has been reported as an early tumor marker in breast cancer 
(D’Arcy et al., 2006). Western blot analysis also showed that the glioblastoma multiforme 
cell line retains the expression of GFAP (figure 5, B) which is a reliable marker of astrocytic 
cells (Moore 1965; Machado et al., 2005). However,literature has shown a negative 
correlation between the degree of malignancy and the expression of GFAP protein in the 
majority of human gliomas (Machado et al., 2005). We also showed that vimentin which has 
been identified in some human glioma cell lines (Roessmann et al., 1983; Rutka et al., 1998) 
was also detectable in this glioma cell line (figure 8, C). Machado et al., 2005 claimed that the 
effect of vimentin filaments on the invaginations or folding in the nucleus is not absolute 
and raised the possibility that this nuclear configuration could be an indirect effect of a 
metabolic difference between cells that contain or lack organized vimentin filaments. To all 
appearances, ours and previous study results indicated that the absence or presence of an 
organized vimentin filament network do not affect the shape of the cell. However, 
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interestingly S100 protein that was originally identified as brain specific (Moore, 1965) and 
believed to be expressed in a few types of gliomas was not identified in this cell line. But 
still, literature has shown a negative correlation between the degree of malignancy and the 
expression of GFAP and S100 protein in the majority of human gliomas (Jacques et al., 1981; 
Duffy et al., 1982).  
 
 
Fig. 9. Immunocytochemical staining in glioma cell line (glioblastoma multiforme) at 
passage 6 to passage 17 at 5 x magnification. Note the immunopositive staining for (A) 
BORIS, (B) GFAP and (C) B- tubulin. On the other hand, cells were S-100- negative stained 
(D). The negative control is the slide that stained with secondary antibody only. 
Immunopositive (figure 9) and western blotting results for BORIS indicates that the tumor-
antigenic polypeptide is expressed in the glioma cell lines. These results suggest that BORIS 
might play an important role in regulating the tumorigenesis pathway. And if that persists, 
BORIS can be manipulated as a biomarker in detecting the presence of tumoric condition in 
glial cells in an uninvasive way and at the very early stage. Deeper understanding of the 
place and the role of BORIS in that exact molecular pathway, gave us a good chance in 
preventing or disrupting the tumorigenesis pathway. This could lead to the application of 
genetic therapy in treating glioma patients. Understanding and moving towards that goal, 
require us to study deeper and not just stop at this preliminary study. This cell line showed 
negative expression of MAP-2, a neuron-marker which suggests that the tumor cell line is 
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not originated from neuron cell and the negative expression of oligodendrocytes suggested 
that the cells absolutely not oligodendrocytes.  
The newly established cells entered into an exponential growth phase at the 16th passage, 
when the cells grew aggressively in the culture. The high growth rate was observed for 
these successive passages when the population doubling time of the glioblastoma 
multiforme cell line was about 6 hrs at 37°C and the saturation cell density was reached at 
3.3 × 105 cells/cm2 (graph 1). The cells showed continuous progressive growth until day 7 
without showing any sign of senescence. On the other hand, the growth kinetic of the 
DBTRG-05MG cells, used as a reference cells in this study, achieved population doubling 
time of approximately 34 to 41 hours. The saturation density of the cells reached 8.3 X 105 
cells/ well (Kruise et al., 1992). 
In comparison, DBTRG-05MG the well known established glioma cell line, introduced by 
Kruse et al. in 1992, showed rounded and spindle shape cells with fibroblast-like cells 
(figure 7).This is exactly different with our newly established clinically derived glioma but 
the heterogeneity of the morphology was in parallel with most studies done in glioma 
cells. 
The study of characterization of the ATCC derived cell line also revealed positive expression 
of BORIS, GFAP, Vimentin (figure 8) and S100 proteins (Kruise et al., 1992). This profiling 
was in parallel with our newly established glioma cells with the exclusion of S100 protein. 
Figure 9 (D) showed our newly established cells immunonegative for S100 protein. The 
comparison of protein expression in both DBTRG-05MG the ATCC derived glioma cell line 
and our newly established glioma  is shown and  summarized  in Figure 11 and Table 1. 
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Graph 1. Growth kinetic of glioblastoma multiforme cell line for passage 16 (linear graph) 
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Fig. 10. Morphology of DBTRG-05MG (ATCC derived glioma cell line) under phase contrast 
microscopy.  Rounded cell with fibroblastic-like cells. 
 
 
 
 
 
 
Fig. 11. Immunopositive of BORIS in DBTRG-05MG ATCC derived cell line. The negative 
control is the slide that stained with secondary antibody only (not shown). 
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Specificity 
Cells 
Clinically derived glioma 
(this study) 
ATCC derived glioma 
(DBTRG-05MG) 
BORIS + +    (Kruise et al., 1992) 
GFAP + +   (this study) 
Vimentin + +   (Kruise et al., 1992) 
S100 - +   (Kruise et al., 1992) 
Table 1. The summary of protein studies based on immunocytochemistry and western 
blotting assay for established glioma cell line in comparison with the ATCC derived glioma 
cell line (adapted from Kruise et al., 1992). 
 
 
Fig. 12. Amplification plots of BORIS mRNA expression using Taqman probe master mix. 
The result showed that BORIS mRNA was unexpressed in DBTRG-05MG (ATCC derived 
glioma), ATCC derived normal osteoblast, ATCC derived normal glial cell lines and in no 
template controls (A). BORIS mRNA was expressed in positive control osteosarcoma U2OS 
cells (ATCC derived) detected at ~38 cycles (B). 
The expression of BORIS mRNA was not found in DBTRG-05MG ATCC derived glioma cell 
line (Figure 12) although we observed the positive expression of BORIS protein in the same 
sample. Recently Hines et al., 2010 has reported that BORIS mRNA was not expressed in 
most human breast cancer cell lines and tumors.  Furthermore expression of BORIS mRNA 
showed no significant difference between normal and prostate cancer tissues overall and no 
relationship was seen to clinical parameters (D’Arcy et al., 2006). This strengthened the 
study done by Renaud et al., in 2007 that BORIS involved in complex mechanism and it is 
promoter dependent gene. Therefore, at this stage we expected the undetected expression of 
BORIS mRNA in our newly established clinically derived glioma primary cell line with 
positive expression of BORIS protein in the same clinical derived sample.   
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4. Conclusion 
We established our glioblastoma multiforme cell line with the basic characteristics including 
the morphology study, surface antigen profile, protein study and also the growth analysis. 
This cell line which was derived from our clinical sample would be useful for studies on the 
molecular basis of malignancy and progression of glioma as well as in studies of glioma 
treatment. BORIS has been shown to be expressed in our glioma primary cell line. This 
study has strengthened the suggestion of a previous study (D’ Arcy et al., 2001) where 
BORIS could play an important role in the early diagnosis of glioma which requires further 
study with consideration of its complex behaviour in cancer development as well as the 
splice variants in promoter dependent gene. 
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